Search research articles
Contact Us
Filters
Showing results (871-880 of 888) with videos related to
Page
of 89
Sort By:
Journal of Vascular and Interventional Radiology : JVIR
|
June 30, 2009
Quality improvement guidelines for percutaneous management of acute limb ischemia
Dheeraj K Rajan, Nilesh H Patel, Karim Valji, et al.
Nature Medicine
|
October 6, 2020
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
Alain P Algazi, Megan Othus, Adil I Daud, et al.
Biorxiv : the Preprint Server for Biology
|
February 6, 2026
Ultra-deep duplex sequencing reveals unique features of somatic evolution in the normal tissues of a family with Li-Fraumeni syndrome
Hunter L Colegrove, Marianne E Dubard-Gault, Henry Marshall, et al.
Journal for Immunotherapy of Cancer
|
September 24, 2016
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
Elizabeth I Buchbinder, Anasuya Gunturi, Jessica Perritt, et al.
Cancer Immunology, Immunotherapy : CII
|
October 8, 2016
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
Ajjai Alva, Gregory A Daniels, Michael K K Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2004
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
David F McDermott, Meredith M Regan, Joseph I Clark, et al.
European Urology
|
May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial
Primo N Lara, Catherine Tangen, Elisabeth I Heath, et al.
Lancet (London, England)
|
July 31, 2023
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial
Christopher W Ryan, Catherine M Tangen, Elisabeth I Heath, et al.
JAMA Oncology
|
December 4, 2015
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B Johnson, Ryan J Sullivan, Patrick A Ott, et al.
British Journal of Cancer
|
December 4, 1998
Chemotherapy for ovarian cancer--a consensus statement on standard practice
M Adams, A H Calvert, J Carmichael, et al.
Page
of 89
Search research articles
Search
Showing results (871-880 of 888) with videos related to
Sort By:
Page
of 89
Journal of Vascular and Interventional Radiology : JVIR
|
June 30, 2009
Quality improvement guidelines for percutaneous management of acute limb ischemia
Dheeraj K Rajan, Nilesh H Patel, Karim Valji, et al.
Nature Medicine
|
October 6, 2020
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
Alain P Algazi, Megan Othus, Adil I Daud, et al.
Biorxiv : the Preprint Server for Biology
|
February 6, 2026
Ultra-deep duplex sequencing reveals unique features of somatic evolution in the normal tissues of a family with Li-Fraumeni syndrome
Hunter L Colegrove, Marianne E Dubard-Gault, Henry Marshall, et al.
Journal for Immunotherapy of Cancer
|
September 24, 2016
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
Elizabeth I Buchbinder, Anasuya Gunturi, Jessica Perritt, et al.
Cancer Immunology, Immunotherapy : CII
|
October 8, 2016
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
Ajjai Alva, Gregory A Daniels, Michael K K Wong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 31, 2004
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
David F McDermott, Meredith M Regan, Joseph I Clark, et al.
European Urology
|
May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial
Primo N Lara, Catherine Tangen, Elisabeth I Heath, et al.
Lancet (London, England)
|
July 31, 2023
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial
Christopher W Ryan, Catherine M Tangen, Elisabeth I Heath, et al.
JAMA Oncology
|
December 4, 2015
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Douglas B Johnson, Ryan J Sullivan, Patrick A Ott, et al.
British Journal of Cancer
|
December 4, 1998
Chemotherapy for ovarian cancer--a consensus statement on standard practice
M Adams, A H Calvert, J Carmichael, et al.
Page
of 89